Skip to main content

Advertisement

Log in

Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Tumor markers are frequently used for screening and monitoring in oncology. We investigated the use of preoperative tumor marker (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA] 15-3) levels in estimating the prognosis of breast cancer patients.

Methods

We conducted a retrospective study in patients who underwent breast cancer surgery at National Cancer Center Hospital between 1975 and 1994 and whose serum CEA (n = 1663) and CA 15-3 (n = 1500) levels were measured prior to operation. When we excluded patients with stage IV disease from the study, the CEA level was within the normal range in 1470 patients, while 150 patients had an elevated CEA level. For CA 15-3, 1395 patients were within the normal range, while 70 patients exhibited an elevated level.

Results

The 5-year and 10-year survival rates for patients with normal CEA levels were 87% and 76%, respectively. However, the 5-year and 10-year survival rates for patients with elevated CEA levels were 76% and 65%, respectively. At both time points, patients with normal CEA levels had higher survival rates (P < 0.05). The 5-year and 10-year survival rates for the patients with normal CA 15-3 levels were 86% and 76%, respectively, while only 71% and 52% patients with elevated CA 15-3 levels survived at 5 and 10 years, respectively. These differences were also significant (P < 0.05). However, there were no significant differences in disease-free survival (DFS) according to CEA or CA 15-3 levels.

Conclusion

There was a positive correlation between CEA levels and CA 15-3 levels and patient prognosis. Thus, the levels of these tumor markers may help to determine prognosis in breast cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris L, Frische H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Clinical practice guidelines of American Society of Clinical Oncology. J Clin Oncol 25:5287–5312

    Article  PubMed  CAS  Google Scholar 

  2. Japanese Breast Cancer Society (2004) General rules for clinical and pathological recording of breast cancer, 15th edn (in Japanese). Kanehara, Tokyo

  3. Molina R, Filella X, Alicarte J, et al. (2003) Prospective evaluation of CEA and CA 15-3 in patients with locoregional breast cancer. Anticancer Res 23:1035–1042

    PubMed  CAS  Google Scholar 

  4. Hayes DF, Zurawski VR, Kufe DW (1986) Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542–1546

    PubMed  CAS  Google Scholar 

  5. Molina R, Filella X, Mengual P, et al. (1990) MCA in patients with breast cancer: correlation with CEA and CA 15-3. Int J Biol Markers 5:14–21

    PubMed  CAS  Google Scholar 

  6. Molina R, Ballesta AM (1991) Evaluation of several tumor markers (MCA, CA 15-3, BCM, and CA549) in tissue and serum of patients with breast cancer. In: Ceriani RL (ed) Breast epithelial antigens. Molecular biology to clinical applications. Plenum, New York, pp 161–163

    Google Scholar 

  7. Dnistrian AM, Schwartz MK, Greenberg EJ, et al. (1991) Evaluation of CAM26, CAM29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 12:1282–1290

    Article  Google Scholar 

  8. Molina R, Fiella X, Zanon G, et al. (2003) Prospective evaluation of tumor markers (c-erb B-2 oncoprotein, CEA, CA 15-3) in patients with locoregional breast cancer: Anticancer Res 23: 1043–1050

    PubMed  CAS  Google Scholar 

  9. Guadagni F, Ferroni P, Carlini S, et al. (2001) A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 7:2357–2362

    PubMed  CAS  Google Scholar 

  10. Sutterlin M, Bussen S, Trott S, et al. (1999) Predictive value of CEA and CA 15-3 in the follow up of invasive breast cancer. Anticancer Res 19:2567–2570

    PubMed  CAS  Google Scholar 

  11. Gion M, Mione R, Leon AE, et al. (2001) CA27-29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. Eur J Cancer. 37:355–363

    Article  PubMed  CAS  Google Scholar 

  12. Nicolini A, Carpi A, Michelassi C, et al. (2003) Tumour marker guided salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 57:452–459

    Article  PubMed  CAS  Google Scholar 

  13. The GIVIO investigators (1994) Impact of follow up testing on survival and health-related quality of life in breast cancer patients. JAMA 271:1587–1592

    Article  Google Scholar 

  14. Turco M, Cariddi D, Pacini S, et al. (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. JAMA 271:1593–1597

    Article  Google Scholar 

  15. Soletormos G, Nielsen D, Schioler V, et al. (2004) Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481–486

    Article  PubMed  CAS  Google Scholar 

  16. Lumachi F, Brandes AA, Ermani M, et al. (2000) Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res 20:4751–4756

    PubMed  CAS  Google Scholar 

  17. Lumachi F, Brandes AA, Boccagni P, et al. (1999) Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 19:4485–4490

    PubMed  CAS  Google Scholar 

  18. Molina R, Jo J, Filella X, et al. (1999) C-erb b-2 CEA and CA 15-3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 19:2551–2556

    PubMed  CAS  Google Scholar 

  19. Sutterlin M, Bussen S, Trott S, et al. (1999) Predictive value of CEA and CA 15-3 in the follow-up of invasive breast cancer. Anticancer Res 19:2526–2570

    Google Scholar 

  20. Lauro S, Trasatti L, Bordin F, et al. (1999) Comparison of CEA, MCA, CA 15-3 and CA27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 19: 3511–3516

    PubMed  CAS  Google Scholar 

  21. Pectasides D, Pavlidis N, Gogou L, et al. (1996) Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients. Am J Clin Oncol 19:459–464

    Article  PubMed  CAS  Google Scholar 

  22. Jezersek B, Cervek J, Rudolf Z, et al. (1996) Clinical evaluation of potential usefulness of CEA, CA 15-3 and MCA in follow-up of breast cancer patients. Cancer Lett 110:137–144

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Masahiro Uehara.

About this article

Cite this article

Uehara, M., Kinoshita, T., Hojo, T. et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol 13, 447–451 (2008). https://doi.org/10.1007/s10147-008-0773-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0773-3

Key words

Navigation